Scott T, Baker K, Trotter C, Jenkins C, Mostowy S, Hawkey J
Nat Rev Microbiol. 2024; .
PMID: 39604656
DOI: 10.1038/s41579-024-01126-x.
Rossi O, Citiulo F, Giannelli C, Cappelletti E, Gasperini G, Mancini F
NPJ Vaccines. 2023; 8(1):130.
PMID: 37670042
PMC: 10480147.
DOI: 10.1038/s41541-023-00725-8.
Raso M, Arato V, Gasperini G, Micoli F
Int J Mol Sci. 2023; 24(5).
PMID: 36902092
PMC: 10003550.
DOI: 10.3390/ijms24054649.
MacLennan C, Grow S, Ma L, Steele A
Vaccines (Basel). 2022; 10(9).
PMID: 36146457
PMC: 9504713.
DOI: 10.3390/vaccines10091376.
Choy R, Louis Bourgeois A, Ockenhouse C, Walker R, Sheets R, Flores J
Clin Microbiol Rev. 2022; 35(3):e0000821.
PMID: 35862754
PMC: 9491212.
DOI: 10.1128/cmr.00008-21.
Detoxified O-Specific Polysaccharide (O-SP)-Protein Conjugates: Emerging Approach in the Vaccine Development Scene.
Cohen D, Meron-Sudai S, Bialik A, Asato V, Ashkenazi S
Vaccines (Basel). 2022; 10(5).
PMID: 35632431
PMC: 9145086.
DOI: 10.3390/vaccines10050675.
From Kiyoshi Shiga to Present-Day Shigella Vaccines: A Historical Narrative Review.
Herrera C, Schmitt J, Chowdhry E, Riddle M
Vaccines (Basel). 2022; 10(5).
PMID: 35632401
PMC: 9145194.
DOI: 10.3390/vaccines10050645.
Shigella-Controlled Human Infection Models: Current and Future Perspectives.
Clarkson K, Porter C, Talaat K, Kapulu M, Chen W, Frenck Jr R
Curr Top Microbiol Immunol. 2022; 445:257-313.
PMID: 35616717
PMC: 7616482.
DOI: 10.1007/82_2021_248.
Towards a Four-Component GMMA-Based Vaccine against .
Micoli F, Nakakana U, Scorza F
Vaccines (Basel). 2022; 10(2).
PMID: 35214786
PMC: 8880054.
DOI: 10.3390/vaccines10020328.
-Specific Immune Profiles Induced after Parenteral Immunization or Oral Challenge with Either Shigella flexneri 2a or Shigella sonnei.
Clarkson K, Porter C, Talaat K, Frenck Jr R, Alaimo C, Martin P
mSphere. 2021; 6(4):e0012221.
PMID: 34259559
PMC: 8386581.
DOI: 10.1128/mSphere.00122-21.
Quantitative Microbial Risk Assessment of Pediatric Infections Attributable to Ingestion of Fecally Contaminated Domestic Soils in Low-Income Urban Maputo, Mozambique.
Capone D, Bivins A, Knee J, Cumming O, Nala R, Brown J
Environ Sci Technol. 2021; 55(3):1941-1952.
PMID: 33472364
PMC: 7860170.
DOI: 10.1021/acs.est.0c06972.
Homologous and heterologous re-challenge with Salmonella Typhi and Salmonella Paratyphi A in a randomised controlled human infection model.
Gibani M, Jin C, Shrestha S, Moore M, Norman L, Voysey M
PLoS Negl Trop Dis. 2020; 14(10):e0008783.
PMID: 33079959
PMC: 7598925.
DOI: 10.1371/journal.pntd.0008783.
Immune Response Characterization after Controlled Infection with Lyophilized Shigella sonnei 53G.
Clarkson K, Frenck Jr R, Dickey M, Suvarnapunya A, Chandrasekaran L, Weerts H
mSphere. 2020; 5(5).
PMID: 32968012
PMC: 7568644.
DOI: 10.1128/mSphere.00988-19.
Consensus Report on Shigella Controlled Human Infection Model: Conduct of Studies.
Talaat K, Louis Bourgeois A, Frenck R, Chen W, MacLennan C, Riddle M
Clin Infect Dis. 2019; 69(Suppl 8):S580-S590.
PMID: 31816068
PMC: 6901126.
DOI: 10.1093/cid/ciz892.
Consensus Report on Shigella Controlled Human Infection Model: Immunological Assays.
Kaminski R, Pasetti M, Aguilar A, Clarkson K, Rijpkema S, Louis Bourgeois A
Clin Infect Dis. 2019; 69(Suppl 8):S596-S601.
PMID: 31816067
PMC: 6901123.
DOI: 10.1093/cid/ciz909.
Consensus Report on Shigella Controlled Human Infection Model: Clinical Endpoints.
MacLennan C, Riddle M, Chen W, Talaat K, Jain V, Louis Bourgeois A
Clin Infect Dis. 2019; 69(Suppl 8):S591-S595.
PMID: 31816065
PMC: 6901125.
DOI: 10.1093/cid/ciz891.
Role of antigen specific T and B cells in systemic and mucosal immune responses in ETEC and Shigella infections, and their potential to serve as correlates of protection in vaccine development.
Mani S, Toapanta F, McArthur M, Qadri F, Svennerholm A, Devriendt B
Vaccine. 2019; 37(34):4787-4793.
PMID: 31230883
PMC: 7413037.
DOI: 10.1016/j.vaccine.2019.03.040.
A tale of two bacterial enteropathogens and one multivalent vaccine.
Barry E, Levine M
Cell Microbiol. 2019; 21(11):e13067.
PMID: 31194282
PMC: 6842089.
DOI: 10.1111/cmi.13067.
Serum IgG antibodies to lipopolysaccharide antigens - a correlate of protection against shigellosis.
Cohen D, Meron-Sudai S, Bialik A, Asato V, Goren S, Ariel-Cohen O
Hum Vaccin Immunother. 2019; 15(6):1401-1408.
PMID: 31070988
PMC: 6663123.
DOI: 10.1080/21645515.2019.1606971.
-mediated immunosuppression in the human gut: subversion extends from innate to adaptive immune responses.
Brunner K, Samassa F, Sansonetti P, Phalipon A
Hum Vaccin Immunother. 2019; 15(6):1317-1325.
PMID: 30964713
PMC: 6663138.
DOI: 10.1080/21645515.2019.1594132.
